๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Patent portfolio

United Therapeutics Europe Patents

Full USPTO pharma patent portfolio for United Therapeutics Europe โ€” grant dates, expiration, and drug cross-links.

Patents
3,720
Expiring โ‰ค24m
234

Quick answer

United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months โ€” use filters for patent-cliff planning.

Page 36 of 78

  1. US 9193790

    Use of antagonists of the interaction between HIV GP120 and A4B7 integrin

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9193739

    Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9193769

    Bovine adeno-associated viral (BAAV) vector and uses thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9186406

    Compositions containing nucleosides and manganese and their uses

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9186365

    Antiangiogenic small molecules and methods of use

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9187457

    Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9187516

    Compositions and methods for inhibiting expression of a gene from the Ebola virus

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9181530

    Infectious hepatitis E virus genotype 3 recombinants

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9181253

    Adenosine receptor agonists, partial agonists, and antagonists

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9180198

    Slow-release cilostazol tablet having an improved elution rate and minimal side effects

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9181306

    Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9180133

    Method for treating uterine fibroids

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9181340

    TEM8 antibodies, conjugates thereof, and their use

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9181327

    Anti-HIV domain antibodies and method of making and using same

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9180179

    Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9175062

    Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing human sRAGE, and treatment methods using sRAGE

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9173932

    Vibrio cholerae O139 conjugate vaccines

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9173898

    Methods of treating giardiasis

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9173917

    Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9175057

    Immunogenic peptides and methods of use

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9175033

    Methods for preparing complex multivalent immunogenic conjugates

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9175070

    Neutralizing antibodies to HIV-1 and their use

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9175049

    Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9175038

    Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9176122

    Biomarkers for predicting response to immunosuppressive therapy

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9173931

    Process for preparing polysaccharide-protein conjugate vaccines

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9175264

    Postnatal stem cells and uses thereof

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9169297

    Subgenomic replicons of the flavivirus dengue

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9168266

    Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9168297

    Regulation of skin pigmentation by neuregulin-1 (NRG-1)

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9169296

    Expression and assembly of human group C rotavirus-like particles and uses thereof

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9168291

    ฮฒ-mannosylceramide and stimulation of NKT cell anti-tumor immunity

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9169182

    Chrysophaentin analogs that inhibit FtsZ protein

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9163244

    Suppressors of CpG oligonucleotides and methods of use

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9163236

    Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9163258

    Method for the treatment of obesity

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9163068

    Influenza virus recombinant proteins

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9155801

    Amino acid sequences which enhance peptide conjugate solubility

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9156786

    Process to prepare treprostinil, the active ingredient in remodulinยฎ

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9151762

    Identification of DSG-3 as a biomarker for the detection of metastasis in lymph nodes

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9150926

    Diagnosis and treatment of adrenocortical tumors using human microRNA-483

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9150644

    Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9144604

    Vaccine for Shigella

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9139595

    Biologically active macrolides, compositions, and uses thereof

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9140687

    Renal cell carcinoma biomarkers

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9133253

    Ricin vaccine and methods of making thereof

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9133478

    Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9133250

    Proteins with repetitive bacterial-Ig-like (Big) domains present in Leptospira species

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does United Therapeutics Europe have?

3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do United Therapeutics Europe patents expire?

234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources ยท Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates โ€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.